Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Key Highlights
- ➤Allogene schedules UBS Global Biopharma Conference presentation for November 16
- ➤Allogene schedules Jefferies Global Healthcare Conference presentation for November 18
- ➤Allogene schedules Piper Sandler healthcare conference presentation for December 2
- ➤Allogene develops off-the-shelf CAR T candidates for cancer and autoimmune disease
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conferences in November and December 2026. * UBS Global Biopharma Conference Monday, November 16 11:20 AM GMT / 6:20 AM ET London * Jefferies Global Healthcare Conference Wednesday, November 18 9:30 AM GMT / 5:30 AM ET London
* Piper Sandler 38th Annual Healthcare Conference Wednesday, December 2 Time TBD New York Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days.
Get started
Create a free account to read the full story.